Table 1 Baseline patients’ characteristics in the cohort of 643 patients and in the 3 groups of patients stratified according to the time elapsed from last MI
All | Time from MI > 40 days and < 1,5 years | Time from MI ≥ 1,5 years and < 7 years | Time from MI ≥ 7 years | |
|---|---|---|---|---|
N = 643 | N = 158 | N = 171 | N = 314 | |
Age, years § | ||||
Mean (±SD) | 66.7 (±9.4) | 66.4 (±11.1) | 64.6 (±9.3) | 67.9 (±8.4) |
Male § | 568 (88.3%) | 129 (81.6%) | 152 (88.9%) | 287 (91.4%) |
NYHA | ||||
I | 55 (8.6%) | 12 (7.6%) | 20 (11.8%) | 23 (7.3%) |
II | 315 (49.3%) | 73 (46.5%) | 89 (52.7%) | 153 (48.9%) |
III | 256 (40.1%) | 65 (41.4%) | 57 (33.7%) | 134 (42.8%) |
IV § | 13 (2.0%) | 7 (4.5%) | 3 (1.8%) | 3 (1.0%) |
LVEF, % | ||||
Mean (±SD) | 25.9 (±5.0) | 26.2 (±5.1) | 25.6 (±5.0) | 26.0 (±4.9) |
Median (IQR) | 26 (23, 30) | 26 (24, 30) | 26 (21, 30) | 26 (23, 30) |
History of permanent atrial fibrillation § | 46 (7.2%) | 8 (5.1%) | 6 (3.5%) | 32 (10.2%) |
LBBB | 168 (26.1%) | 32 (20.3%) | 46 (26.9%) | 90 (28.7%) |
Hypertension | 301 (48.6%) | 79 (52.0%) | 85 (51.8%) | 137 (45.2%) |
Diabetes | 182 (29.4%) | 47 (30.9%) | 45 (27.3%) | 90 (29.7%) |
CABG § | 239 (37.2%) | 33 (20.9%) | 64 (37.4%) | 142 (45.2%) |
PTCA § | 247 (38.4%) | 86 (54.4%) | 63 (36.8%) | 98 (31.2%) |
Amiodarone | 154 (24.2%) | 33 (21.2%) | 48 (28.2%) | 73 (23.5%) |
Statins | 319 (49.8%) | 78 (49.7%) | 91 (53.5%) | 150 (47.9%) |
Diuretics | 545 (85.0%) | 137 (86.7%) | 140 (82.4%) | 268 (85.6%) |
Beta blockers | 497 (77.8%) | 128 (81.5%) | 126 (74.1%) | 243 (77.9%) |
ACE inhibitors | 507 (79.1%) | 131 (82.9%) | 129 (75.9%) | 247 (78.9%) |
Angiotensin II receptor inhibitors | 52 (8.2%) | 12 (7.7%) | 13 (7.7%) | 27 (8.7%) |
Single-chamber ICD | 341 (53.0%) | 92 (58.2%) | 87 (50.9%) | 162 (51.6%) |
Dual-chamber ICD | 173 (26.9%) | 36 (22.8%) | 54 (31.6%) | 83 (26.4%) |
CRT-ICD | 129 (20.1%) | 30 (19.0%) | 30 (17.5%) | 69 (22.0%) |
Time from last MI, years | ||||
Median (IQR) | 7.0 (1.6, 12.8) | 0.5 (0.3, 0.9) | 4.0 (2.7, 5.5) | 12.9 (9.9, 17.4) |